Mycovia Pharmaceuticals Announces Partnership with Gedeon Richter to Commercialize and Manufacture VT-1161 for Recurrent Vulvovaginal Cand
Agreement expands Mycovia’s international commercialization plans for VT-1161 to European countries, Latin America, Australia, Russia and Commonwealth of Independent States
Mycovia will continue to quickly develop VT-1161 as a possible first FDA-approved remedy for recurrent vulvovaginal candidiasis
DURHAM, N.C.–( COMPANY WIRE )–Mycovia Pharmaceuticals, Inc. today announced it offers entered into a license that is exclusive development and technology transfer contract with Gedeon Richter Plc., situated in Budapest, Hungary, to commercialize and produce VT-1161 in European countries, Latin America, Australia, Russia as well as other CIS nations. VT-1161, an dental antifungal item prospect, is in period 3 medical studies when it comes to treatment of Recurrent Vulvovaginal Candidiasis (RVVC), a debilitating, chronic infectious condition that impacts almost 138 million females global every year.
“We are excited to partner with Gedeon Richter, a business with strong market leadership in women’s health, to build up and commercialize VT-1161, our prospective first treatment that is FDA-approved RVVC,” said Patrick Jordan, CEO of Mycovia and Partner at NovaQuest Capital Management, which formed Mycovia in 2018 to advance VT-1161 in worldwide areas. “VT-1161 is well placed to deal with the needs of the an incredible number of women that have problems with vexation, discomfort and psychological stress due to RVVC and tend to be searching for a treatment option that is new.